Literature DB >> 8703002

Long-acting growth hormones produced by conjugation with polyethylene glycol.

R Clark1, K Olson, G Fuh, M Marian, D Mortensen, G Teshima, S Chang, H Chu, V Mukku, E Canova-Davis, T Somers, M Cronin, M Winkler, J A Wells.   

Abstract

Derivatives of human growth hormone (hGH) of increasing size were produced by reaction with the N-hydroxysuccinimide ester of polyethylene glycol-5000 (PEG5000), a 5-kDa reagent that selectively conjugates to primary amines. By adjusting the reaction conditions and purification procedure, it was possible to isolate hGH derivatives containing up to seven PEG moieties that altered the Stokes radius and thereby the effective molecular masses of the unmodified hormone from 22 to 300 kDa. Fortunately, the most reactive amines were ones that did not lie in either of the two sites important for receptor binding. Nonetheless, increasing the level of PEG modification linearly reduced the affinity of hGH for its receptor and increased the EC50 in a cell-based assay up to 1500-fold. Most of the reduction in affinity was the result of slowing the association rate for the receptor. The clearance rate of hGH in rats was inversely proportional to effective molecular weight and closely fit a filtration model. We have tested the potency of these analogs by injecting them daily or every 6 days into hypophysectomized rats and determining the effects on body and organ growth. The efficacy of these analogs was optimal for hGH conjugated with 5 eq of PEG5000, and the potency was increased by about 10-fold compared with unmodified hGH. Such PEG-hGH derivatives show promise as long-acting alternatives to daily injections of hGH. More generally these studies show that improving hormone clearance properties, even at the expense of reducing receptor binding affinity, can lead to dramatic increases in hormone efficacy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703002     DOI: 10.1074/jbc.271.36.21969

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.

Authors:  T Sakane; W M Pardridge
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 2.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Somatostatin analog and pegvisomant combination therapy for acromegaly.

Authors:  Sebastian J C Neggers; Aart Jan van der Lely
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

Review 4.  Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.

Authors:  Ryan G Soderquist; Melissa J Mahoney
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

5.  Optimized clinical performance of growth hormone with an expanded genetic code.

Authors:  Ho Cho; Tom Daniel; Ying Ji Buechler; David C Litzinger; Zhenwei Maio; Anna-Maria Hays Putnam; Vadim S Kraynov; Bee-Cheng Sim; Stuart Bussell; Tsotne Javahishvili; Sami Kaphle; Guillermo Viramontes; Mike Ong; Stephanie Chu; G C Becky; Ricky Lieu; Nick Knudsen; Paola Castiglioni; Thea C Norman; Douglas W Axelrod; Andrew R Hoffman; Peter G Schultz; Richard D DiMarchi; Bruce E Kimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

6.  Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins.

Authors:  K C Lee; S C Moon; M O Park; J T Lee; D H Na; S D Yoo; H S Lee; P P DeLuca
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

7.  PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.

Authors:  Ryan G Soderquist; Erin D Milligan; Evan M Sloane; Jacqueline A Harrison; Klarika K Douvas; Joseph M Potter; Travis S Hughes; Raymond A Chavez; Kirk Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2009-12       Impact factor: 4.396

8.  PEGylation of interleukin-10 for the mitigation of enhanced pain states.

Authors:  Ryan G Soderquist; Erin D Milligan; Jacqueline A Harrison; Raymond A Chavez; Kirk W Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2010-06-01       Impact factor: 4.396

9.  Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity.

Authors:  Haeshin Lee; Tae Gwan Park
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.